Abstract:Malignant melanoma is the most aggressive form of skin cancer. Standard treatment options include surgery, radiation therapy, systemic chemotherapy, targeted therapy, and immunotherapy. Combining these modalities often yields better responses. Surgery is suitable for localized cases, sometimes involving lymph node dissection and biopsy, to assess the spread of the disease. Radiation therapy may be sometimes used as a standalone treatment or following surgical excision. Systemic chemotherapy, while having low response rates, is utilized as part of combination treatments or when other methods fail. The development of resistance to systemic chemotherapies and associated side effects have prompted further research and clinical trials for novel approaches. In the case of advanced-stage melanoma, a comprehensive approach may be necessary, incorporating targeted therapies and immunotherapies that demonstrate significant antitumor activity. Targeted therapies, including inhibitors targeting BRAF, MEK, c-KIT, and NRAS, are designed to block the specific molecules responsible for tumor growth. These therapies show promise, particularly in patients with corresponding mutations. Combination therapy, including BRAF and MEK inhibitors, has been evidenced to improve progression-free survival; however, concerns about resistance and cutaneous toxicities highlight the need for close monitoring. Immunotherapies, leveraging tumor-infiltrating lymphocytes and CAR T cells, enhance immune responses. Lifileucel, an FDA-approved tumor-infiltrating lymphocyte therapy, has demonstrated improved response rates in advanced-stage melanoma. Ongoing trials continue to explore the efficacy of CAR T-cell therapy for advanced melanoma. Checkpoint inhibitors targeting CTLA-4 and PD-1 have enhanced outcomes. Emerging IL-2 therapies boost dendritic cells, enhancing anticancer immunity. Oncolytic virus therapy, approved for advanced melanoma, augments treatment efficacy in combination approaches. While immunotherapy has significantly advanced melanoma treatment, its success varies, prompting research into new drugs and factors influencing outcomes. This review provides insights into current melanoma treatments and recent therapeutic advances.

Melanoma—Modern Treatment for Metastatic Melanoma

Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care

Immunomodulatory therapy for melanoma: ipilimumab and beyond

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma

Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients

Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Therapeutic options in cutaneous melanoma: latest developments

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Recent advances of immune checkpoint inhibitors for treatment of melanoma

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

Advances in treatment of melanoma with immunotherapy

Ipilimumab in the Treatment of Metastatic Melanoma: A Summary of Recent Studies

Targeting metastatic melanoma

A Review of Current and Pipeline Drugs for Treatment of Melanoma